DreaMed Advisor Pro

DreaMed Advisor Pro is an AI-driven decision-support tool that assists clinicians in optimizing insulin therapy for type 1 diabetes patients using insulin pumps by analyzing patient-specific data to generate personalized dosing recommendations. The system's methodology, which emulates endocrinologist expertise, has been clinically validated to improve glycemic control, evidenced by increased time-in-range and reduced hypoglycemia.

DreaMed Advisor Pro is a sophisticated decision-support software engineered for clinicians managing individuals with type 1 diabetes who use insulin pumps. The system operates by having healthcare providers upload comprehensive patient data, including insulin pump information, continuous glucose monitor (CGM) readings, and self-monitored blood glucose (SMBG) logs. Its core artificial intelligence then meticulously analyzes the complex interplay between glucose levels and insulin administration to generate tailored recommendations for basal rates, carbohydrate ratios, and correction factors. These recommendations are presented to the clinicians, who retain the authority to review, adjust, and ultimately approve them before implementation, ensuring a collaborative approach to patient care. The software's efficacy is rooted in an algorithm designed to emulate the intricate decision-making processes characteristic of experienced endocrinologists. Clinical trials have substantiated its benefits, demonstrating that its utilization leads to a statistically significant increase in CGM time-in-range for patients and a notable reduction in episodes of hypoglycemia when compared to standard care protocols. Functioning as an adjunctive tool, DreaMed Advisor Pro aims to streamline and enhance the optimization of insulin therapy, ultimately empowering clinicians to achieve better glycemic outcomes for their patients with type 1 diabetes.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AI algorithm in DreaMed Advisor Pro specifically emulate the decision-making patterns of endocrinologists, and what are the key variables it prioritizes?; What were the specific demographic and clinical characteristics (e.g., age, duration of diabetes, baseline A1c) of the patient populations in the clinical trials demonstrating improved time-in-range and reduced hypoglycemia?; Beyond basal rates, carbohydrate ratios, and correction factors, are there plans to expand the software's recommendations to include other aspects of diabetes management, such as exercise or dietary pattern adjustments?; What is the typical learning curve or integration time for clinicians to effectively utilize DreaMed Advisor Pro in their routine practice, and what support mechanisms are in place?; How does DreaMed Advisor Pro account for acute influencing factors such as illness, stress, or significant deviations from routine that might impact insulin sensitivity and glucose levels?